{Reference Type}: Journal Article
{Title}: Repositioning and investigational drugs for Zika virus infection treatment: a patent review.
{Author}: G Viveiros Rosa S;Fierro IM;C Santos W;
{Journal}: Expert Opin Ther Pat
{Volume}: 30
{Issue}: 11
{Year}: Nov 2020
{Factor}: 6.714
{DOI}: 10.1080/13543776.2020.1811854
{Abstract}: <B>BACKGROUND: </B>Zika virus (ZIKV) is transmitted to humans throughout bites of Aedes mosquitoes. ZIKV infection may be asymptomatic in most cases, but it may cause fever, headache, muscle pain, and rash. Guillain-Barré syndrome also may be associated with the infection. Furthermore, the Pan American Health Organization informed 3,715 cases of the congenital ZIKV syndrome (CZS) in the Americas from 2015 - 2017, which may include microcephaly and other craniofacial deformities.<BR><B>UNASSIGNED: </B>This review identifies patent documents on repositioning for ZIKV infection treatment of already approved drugs or phases II/III investigated drugs for other diseases. Thirty-six patents were found reporting compounds with anti-ZIKV activity with application dates ranging from 2015 to 2019.<BR><B>UNASSIGNED: </B>The main drugs claimed in patents were ribavirin, sofosbuvir, and alpha interferons. Preventing CZS is one of the most significant challenges in ZIKV infection. Therefore, repositioning sofosbuvir and niclosamide, that pose no danger for pregnant women, is a particular issue to be considered for clinical tests involving ZIKV disease. Given the substantial costs and developing time of new a drug, repositioning of old drugs is becoming an attractive alternative for diseases with neglected treatments.